Peptide-developer Xenome has signed a collaboration deal with Amylin Pharmaceuticals to develop novel peptide therapeutics for a range of metabolic and musculoskeletal diseases. Australia's Xenome separately announced that Amylin is making a $5 million equity investment in the company, part of a $10 million financing package.
- see the release [1] on the development deal
- check out this release [2] on the financing
Related Articles:
Psychogenics, Amylin create new development company. Report [3]
Amylin reports weight-loss success with Symlin. Report [4]
Links:
[1] http://www.fiercebiotech.com/press-releases/press-release-xenome-enters-joint-research-collaboration-discover-novel-peptide-thera
[2] http://www.fiercebiotech.com/press-releases/press-release-xenome-receives-syndicated-us-10-million-equity-investment-queensland-b
[3] http://www.fiercebiotech.com/story/psychogenics-amylin-create-new-development-company/2007-01-30
[4] http://www.fiercebiotech.com/story/amylin-reports-weight-loss-success-with-symlin/2005-06-03